Why some cases of IgA nephropathy resist conventional and new therapies: a real-life observational look
Official title: RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN)
Run by Assistance Publique - Hôpitaux de Paris · NCT06926244 · Data updated 2026-11-12
This project will collect real-world data from adults with biopsy-proven IgA nephropathy to see which patients keep having proteinuria or kidney decline despite modern nephroprotective measures and newer treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 800 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris) |
| Status | Recruiting |
| Started | June 23, 2025 |
| Main results expected | April 2028 |
| Study ends | April 2029 |
| Registry record updated | June 23, 2026 |
| Trial ID | NCT06926244 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age ≥18) with a renal biopsy after 2017 showing IgA deposits consistent with IgA nephropathy who agree to use of their clinical data.
✕Probably not a fit
Children, patients without a biopsy-confirmed diagnosis or with biopsies dated before 2017, and those who do not consent to data use would not be eligible and therefore would not benefit from this registry's findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational, real-world registry enrolling adults (≥18) with renal biopsy–confirmed IgA nephropathy diagnosed since 2017 and who consent to use of their clinical data. Clinicians will record baseline biopsy features including MEST-C, treatments received (RAS blockade, SGLT2 inhibitors, endothelin-1 antagonists, steroids, and other immunomodulators), and longitudinal outcomes such as persistent proteinuria and renal function change. The study will analyze which clinical, histologic, and treatment factors are associated with treatment resistance and progressive kidney dysfunction. No investigational drugs are given; the goal is to describe real-life treatment patterns and predictors of poor response to currently available therapies.
Why it matters
Potential benefit: If successful, the project could help identify which patients are likely to resist current therapies and guide more personalized treatment and follow-up strategies.
How similar studies have gone: Some randomized trials (for example with SGLT2 inhibitors) have shown kidney-protective effects including in IgAN subgroups, but using a real-world registry tied to histology to identify predictors of treatment resistance is relatively novel and not yet validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient: age ≥ 18 years * Renal biopsy performed after 2017 showing IgA deposits leading to the diagnosis of IgAN (the date of diagnosis being the index date) * Informed patient and who does not object to the use of his data Exclusion Criteria: \- None
Where it's running
-
Nephrology department, Hospital Pitié - Salpêtrière (ASSISTANCE PUBLIQUE HOPITAUX DE PARIS AP-HP)
Paris, France Recruiting
Study contacts
- Study coordinator: Khalil EL KAROUI, PhD
- Email: khalil.el-karoui@aphp.fr
- Phone: +33 1 56 01 63 17
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
JADE101 in IgA Nephropathy (phase 3, blinded)
This phase 3 study tests whether JADE101 helps adults with IgA nephropathy more than a placebo.
-
Personalized IgA Nephropathy treatment guided by Gd-IgA1 monitoring
This study tests whether regularly checking a biomarker called Gd-IgA1 to guide treatment with Nefecon or telitacicept helps people with IgA nephropathy or related nephritis respond better.
-
Long-term safety and effectiveness of HSK39297 tablets in IgA nephropathy patients who completed prior study
This phase 2 trial tests whether taking HSK39297 once daily for IgA nephropathy is safe over the long term and helps reduce protein in the urine for patients who completed a previous study and meet criteria.
-
Everest001: a medicine for certain kidney diseases to see if it helps adults
This study tests EVER001 in adults with FSGS, MCD, or IgA nephropathy to see if it can help reduce protein in the urine and improve kidney function.
-
Nefecon as a maintenance therapy to prevent relapse in IgA nephropathy
This study tests whether continuing Nefecon after initial remission can lower the chance of relapse in adults with IgA nephropathy.
-
CD19/BCMA UCART for B cell–related autoimmune diseases
This early-stage study tests QT-219CX, a universal allogeneic CAR-T cell therapy that targets CD19 and BCMA, in people with refractory B-cell–related autoimmune diseases to see if it can be given safely and provide early signs of benefit.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.